NCT07428356 Histotripsy for Ablation of Liver Tumours in Asia
| NCT ID | NCT07428356 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Cancer Centre, Singapore |
| Condition | Liver Malignant Tumors |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-11-07 |
| Primary Completion | 2027-11-07 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The HALT study aims to evaluate histotripsy in an Asian population for both primary (HCC, CCA) and secondary liver malignancies with liver-limited or oligoprogressive disease. In addition to safety and local control, the study incorporates translational endpoints including immune profiling (PBMCs, cytokines), microbiome shifts, and optional tumour biopsies. This trial will provide critical data on the feasibility, tolerability, and biological impact of histotripsy in a region with the highest burden of liver cancer.
Eligibility Criteria
Inclusion Criteria: 1. Age ≥21 years at the time of consent. 2. Histologically/cytologically confirmed cancers (imaging diagnosis as per AASLD allowed for HCC): A) Liver limited malignancies (primary or secondary) not eligible for/declined resection or other locoregional treatment modalities. B) All solid cancer patients (e.g., HCC, colorectal, breast, pancreatic cancers etc) undergoing systemic therapy with oligoprogressive liver disease (defined as ≤ 3 liver limited progressive lesions, ≤ 3 cm in maximum diameter having received \> 3 months of systemic therapy). 3. Characteristics of hepatic lesions intended for treatment: * Up to 3 hepatic lesions. * Tumour ≤ 3 cm in longest diameter. * Lesion(s) must be visible and targetable by ultrasound. 4. ECOG Performance Status 0-1. 5. Child-Pugh class A or B7 liver function for patients with underlying cirrhosis. 6. Adequate hematologic and organ function within 14 days prior to treatment: * Haemoglobin ≥ 9.0 g/dL * Platelets ≥ 75,000/mm³ *